{
  "ptid_time": "009_S_4903_2012-09-11",
  "img_path": "/data/qiuhui/data/adni/images/009_S_4903/2012-09-11/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 39,112 mm³, 39.3% above the reference mean. With a Z-score of 0.90 (81.6th percentile), this represents normal volume ; whole brain volume measures 782,588 mm³, 19.7% below the reference mean. With a Z-score of -2.48 (0.7th percentile), this represents significant atrophy; entorhinal cortex volume measures 1,490 mm³, 59.4% below the reference mean. With a Z-score of -3.65 (0.0th percentile), this represents profound atrophy; fusiform gyrus volume measures 13,330 mm³, 21.6% below the reference mean. With a Z-score of -1.97 (2.4th percentile), this represents moderate atrophy; middle temporal gyrus volume measures 13,345 mm³, 30.4% below the reference mean. With a Z-score of -2.64 (0.4th percentile), this represents significant atrophy. ",
  "text_data": "Age is 77.2 years. Gender is Female. Education: 12 years. MMSE: 28.0. MoCA: 20.0. Logical Memory: 3.0. APOEε4 alleles: 1.0. Biomarker levels: Florbetapir (AV45): 1.19 SUVR (normal ); Amyloid beta: 854.80 pg/mL (normal ); Total tau: 287.40 pg/mL (normal ); Phosphorylated tau: 27.50 pg/mL (normal ). ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The imaging data shows significant atrophy in whole brain volume, entorhinal cortex, fusiform gyrus, and middle temporal gyrus, which are regions commonly affected in Alzheimer's disease. Despite normal CSF biomarkers (Aβ, T-tau, P-tau) and AV45 (amyloid PET), the cognitive scores (MoCA 20, MMSE 28) suggest mild cognitive impairment (MCI), with the MMSE being less sensitive to early deficits.  \n\n**Diagnosis:** **MCI** (likely amnestic subtype given entorhinal atrophy, though non-amnestic cannot be ruled out without detailed neuropsych testing)  \n\n**Confidence:** **Medium** (due to conflicting biomarkers—normal amyloid/tau but significant atrophy and cognitive decline; could represent a non-AD neurodegenerative process, but AD is still plausible given the regional atrophy pattern).  \n\n**Note:** If follow-up shows progression to dementia with worsening atrophy/memory, the diagnosis may shift to **dementia** (likely AD variant). A tau PET scan or repeat CSF could help clarify if this is a tauopathy-predominant or non-AD pathology (e.g., TDP-43).",
  "timestamp": "2025-07-25T22:24:19.219194"
}